Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

http://www.wikidata.org/entity/Q37146673

about

Non-small cell lung cancer: current treatment and future advances Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer Molecular pathways and therapeutic targets in lung cancer BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.The MAPK pathway across different malignancies: a new perspective.Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.Increased BRAF copy number in lung adenocarcinoma Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations BRAF gene: From human cancers to developmental syndromes.Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.Lung cancer in women: an overview with special focus on Spanish women.Epidermal growth factor receptor mutations in lung adenocarcinoma.Prognostic and predictive biomarkers in lung cancer. A review.Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Emerging drugs for squamous cell lung cancer.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Pharmacogenomics in the treatment of lung cancer: an update.The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Diagnosis and Molecular Classification of Lung Cancer.Lung Cancer Biomarkers.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

P2860

Q26740333-80CFD45B-82EC-4869-BB7B-66161C192FDB Q26747276-4F1BA93B-D5F1-4475-A3F0-3D6A7320E980 Q30458424-66F8F46F-4295-473E-8303-61F01E493F57 Q33560928-262E4D1B-709B-4CF2-8D50-1E2700326551 Q33621342-5C37D633-9ED2-4295-BC39-80AB61BA6575 Q33688872-BE394F1E-993A-472F-A92D-0CB7D269F565 Q33826001-5CB360F4-9928-428D-AE46-F6A9126674B7 Q34388696-68EAB038-7F3C-418B-8E09-E72FD1DB3F5F Q34459097-DE0C4A52-9628-43E5-A5E0-47440F050791 Q34610381-C43549E9-3A90-4C85-8035-E1C4DDF705A6 Q34993692-7D1D7883-F5A2-4522-8E28-35120E9FE1D6 Q35007886-51F879FF-EC8F-4145-8AC8-E5D198F308BE Q35136424-DA86B73D-D11B-4470-9EA8-475AC1A205F4 Q35663416-D022F036-49CF-45A7-AD51-348D482B3AF9 Q35671830-85D2D47A-BE6D-482A-89CC-FF39C2C36A8D Q35712214-38F1E1E9-FAFF-437F-8FC4-495BF9AD77D3 Q35802430-60846A13-1006-427E-90DC-D08C351396A6 Q36761302-B96F52D3-7AA3-42FB-A987-48AF0005ED09 Q37193792-D8E420FD-1B38-4D64-AB9E-7607D0F49CBB Q37220424-082EABD2-25F6-4674-BDC2-96EB749A2A8D Q37235168-C3808CFC-53AE-4D40-8A7A-CA5E1B534977 Q37632230-6D602FA3-B8D5-4A0B-92F9-AA148CB9485E Q37646889-B0326F1C-4064-4A67-8856-F392284D93CC Q37693426-A3F3E1F6-BDE2-4812-AF93-AAF62BBFD34A Q38166318-5D5D0B73-CEB6-4376-84CE-8345F34612F3 Q38174770-99A3C369-817D-4067-A78E-02CC9FC2053B Q38178187-B2856291-8A9B-424D-B218-C2BBD38DD26E Q38239612-88F7AE1A-94CA-4FB5-A001-53BDC12CD299 Q38306880-20EC8F44-B19C-4BA0-A9CA-B9BD890930BC Q38584814-EDD02A23-924E-40DA-8A24-79A6F55D8E55 Q38596926-8EE85B63-59D9-4C07-8B01-37DC7272386D Q38764663-8A22C957-180E-4915-8B17-E7D7A2C32BE9 Q38930336-DE3311BC-F589-4DAB-8E33-01AB179263A3 Q39027394-4082D0B8-D9D5-4446-8A99-F68641A0F49E Q39294398-D794B6FE-FCE0-448A-BC3E-B9A0935D6363 Q39650208-4CEA178A-DD62-4572-BF8C-7B1CDDE75EE5 Q39698149-C0B64B80-BB46-40A3-9CDF-C2BC67F58250 Q39835396-D38B9788-6A21-4CA5-AB2F-D52A89403803 Q40409078-A7A36B30-8298-457B-B028-4A5DBF9FF056 Q40530427-9A27C423-705F-42F9-8871-ADB0B9BE5448

P2860

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

http://www.wikidata.org/entity/Q37146673

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@en

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@nl

type

label

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@en

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@nl

prefLabel

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@en

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@nl

P1433

Q37146673-3F93447E-F566-4FF6-83E7-2BD04518E8D5

P1476

Q37146673-41F1F0C0-BD4B-461A-AB47-DB29B787F2EF

P2093

Q37146673-51BE798E-2FD4-4ED6-A548-3EDB804F4954

Q37146673-A901A5D0-4B11-4509-B933-CB4F7CFAD9F8

Q37146673-C12B16EE-7875-45A6-80A9-BA26A395458D

Q37146673-C939B396-BEE0-4AA3-A5EA-912943E87411

Q37146673-C9BE5DC2-6CDD-4F2B-AE4E-905E59E1F0DE

Q37146673-D3CCCB50-09B3-4C8F-9174-9E398A425484

Q37146673-E240A9C1-4472-4A93-967A-D0FD374E5BF8

Q37146673-EB4CB26A-4FAE-4630-B225-BD79FE43F6D5

Q37146673-F6D3A0E4-A146-4D5B-8670-5653B3313E5B

P2860

Q37146673-058F0663-1D68-4DBB-BE92-D2A3D5E5BFBE

Q37146673-0E313186-746C-4119-93E3-9C6F1366253A

Q37146673-1E1A1083-983C-4642-8B35-4BED4BE9FB80

Q37146673-22884FB4-540C-4B03-88B8-30931B21974F

Q37146673-275F3CB9-A318-4972-9BB8-83C6BBF3CD1B

Q37146673-3AB9AB9F-AB7D-4BE2-BD5A-22DEA927F531

Q37146673-3DEDE4A9-2257-4287-8021-0617DFC1BCFB

Q37146673-405D4313-F503-4F86-AED4-40C9D5DB8D8A

Q37146673-4BC291AA-8033-4730-A8BB-76E03CDD9DE6

Q37146673-4F3039D0-4A09-4C7A-9055-B78CFE7E477C

P304

Q37146673-A03F3BAE-CE90-44C9-B232-41AA9F3FBCC6

P31

Q37146673-94C16A7B-157E-4C1A-8273-7DC48389AEE5

P356

Q37146673-ECB5BF7D-CABD-452D-AEBE-0167A237C7F8

P407

Q37146673-191CF983-8DA4-4EB3-83F8-1870773424EB

P433

Q37146673-72D4A96A-5E44-43FC-9BFB-A59FDAEB1200

P478

Q37146673-FF067CC1-7EC1-41BD-9897-A27E0AEC1D15

P50

Q37146673-5A492873-85BD-49C3-83CE-5EEECBE30E70

P577

Q37146673-85E126F2-2417-4D16-A768-C371BD24CA3F

P5875

Q37146673-E5EEDC46-018D-4933-85FB-0C19EF7B8F6B

P698

Q37146673-2BBDC3AC-B5FF-4287-9398-7C6A66536BA9

P932

Q37146673-7ADD1051-246A-4EC9-8FD4-FB5DF82BB6C1

P356

1078-0432.CCR-13-0657

P1433

Clinical Cancer Research

P1476

Clinical, pathologic, and biol ...... in non-small cell lung cancer.

@en

P2093

Atsuko Ogino

http://www.w3.org/2001/XMLSchema#string

Beow Y Yeap

http://www.w3.org/2001/XMLSchema#string

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

Christine Lydon

http://www.w3.org/2001/XMLSchema#string

Jeanne Shen

http://www.w3.org/2001/XMLSchema#string

Lynette M Sholl

http://www.w3.org/2001/XMLSchema#string

Mizuki Nishino

http://www.w3.org/2001/XMLSchema#string

Mohit Butaney

http://www.w3.org/2001/XMLSchema#string

Stephanie Cardarella

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Somatic mutations affect key pathways in lung adenocarcinoma

Characterizing the cancer genome in lung adenocarcinoma.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

4532-4540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0657

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247153464

http://www.w3.org/2001/XMLSchema#string

P698

23833300

http://www.w3.org/2001/XMLSchema#string

P932

3762878

http://www.w3.org/2001/XMLSchema#string